Pre-treatment EGFR mutation analysis predicts clinical outcome in a retrospective analysis of 24 non-squamous non-small-cell lung cancer (NSCLC) patients treated with second line afatinib.

被引：0
|
作者：
van der Wekken, Anthonie J. [1 ]
Kuiper, Justine L. [2 ]
Heideman, Danielle A. M. [2 ]
Schuuring, Ed [1 ]
Timens, Wim [1 ]
Thunnissen, Erik [2 ]
Groen, Harry J. M. [1 ]
Smit, Egbert F. [2 ]
机构：
[1] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-3526
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3526
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer
    Laktionov, K.
    Smolin, A.
    Stroyakovskiy, D.
    Moiseenko, V.
    Dvorkin, M.
    Andabekov, T.
    Cheng, Y.
    Liu, B.
    Kozlov, V.
    Odintsova, S.
    Dvoretsky, S.
    Mochalova, A.
    Urda, M.
    Yi, T.
    Li, X.
    Laszlo, U.
    Mueller, V.
    Bogos, K.
    Fadeeva, N.
    Musaev, G.
    Liu, Q.
    Kirtbaya, D.
    Shi, J.
    Gladkov, O.
    Narimanov, M.
    Semiglazova, T.
    Khasanova, A.
    Chovanec, J.
    Andrasina, I
    Szabova, A.
    Rosinska, O.
    Sudekova, D.
    Zsolt, P. -s.
    Ran, F.
    Sun, M.
    Jiang, O.
    Chen, R.
    Zhao, E.
    Liu, C.
    Tan, W.
    Pirmagomedov, A.
    Poddubskaya, E.
    Kislov, N.
    Shumskaya, I.
    Sorokina, I.
    Zinkina-Orikhan, A.
    Linkova, Yu.
    Fogt, S.
    Liaptseva, D.
    Siliutina, A.
    EUROPEAN JOURNAL OF CANCER, 2025, 217
  • [22] Non-small-cell lung cancer (NSCLC) treated with chemotherapy: Survival analysis of 50 patients
    Flores, MM
    Murillo, SM
    Alonso, EG
    Gilart, AB
    CarcellerVidal, JA
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1088 - 1088
  • [23] First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting
    Park, Keunchil
    Lim, Darren Wan-Teck
    Okamoto, Isamu
    Yang, James Chih-Hsin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [24] Phase II Studies of Nivolumab in Patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small-Cell Lung Cancer (NSCLC)
    Nakagawa, Kazuhiko u
    Nishio, Makoto
    Hida, Toyoaki
    Sakai, Hiroshi
    Nogami, Naoyuki
    Atagi, Shinji
    Takahashi, Toshiaki
    Nokihara, Hiroshi
    Saka, Hideo
    Takenoyama, Mitsuhiro
    Fujita, Shiro
    Tanaka, Hiroshi
    Takeda, Koji
    Satouchi, Miyako
    Isobe, Hiroshi
    Maemondo, Makoto
    Goto, Koichi
    Hirashima, Tomonori
    Minato, Koichi
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S270 - S271
  • [25] Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
    Ben Rothwell
    Christopher Kiff
    Caroline Ling
    Thor-Henrik Brodtkorb
    PharmacoEconomics - Open, 2021, 5 : 251 - 260
  • [26] Efficacy of afatinib following osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
    Tamura, Tomohiro
    Okubo, Hatsumi
    Yamada, Yutaka
    Kikkawa, Yasuko
    Yamaguchi, Shozaburo
    Hashimoto, Ikuta
    Kaburagi, Takayuki
    ANNALS OF ONCOLOGY, 2021, 32 : S335 - S335
  • [27] Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
    Hochmair, Maximilian J.
    Morabito, Alessandro
    Hao, Desiree
    Yang, Cheng-Ta
    Soo, Ross A.
    Yang, James C-H
    Gucalp, Rasim
    Halmos, Balazs
    Wang, Lara
    Golembesky, Amanda
    Maerten, Angela
    Cufer, Tanja
    FUTURE ONCOLOGY, 2018, 14 (27) : 2861 - 2874
  • [28] Clinical Outcome and Toxicity Profiles of Patients with EGFR-mutation Positive Non-Small-Cell Lung Cancer
    Munawar, K.
    Sheikh, H.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S621 - S622
  • [29] Effectiveness analysis of second line squamous non-small-cell lung cancer in real-life clinical practice
    Romero Hernandez, I.
    Martinez Bautista, M. J.
    Blanco Sanchez, G.
    Suarez Carrascosa, F. J.
    Dominguez Cantero, M.
    Gallego Munoz, C.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2016, 38 (02) : 590 - 590
  • [30] Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
    Rothwell, Ben
    Kiff, Christopher
    Ling, Caroline
    Brodtkorb, Thor-Henrik
    PHARMACOECONOMICS-OPEN, 2021, 5 (02) : 251 - 260
12345